Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
In Vivo Ready™ Anti-Mouse CD16 / CD32 (2.4G2) Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application 
| IF, FC, IP, FA |
|---|---|
| Isotype | Rat IgG2b |
| Concentration | 2 mg/mL |
| Reactivity | Mouse |
| Formulation | 10 mM NaH2PO4, 150 mM NaCl, pH7.2 |
| Host | Rat |
| Gene ID | 14130 |
|---|---|
| Gene Name | Fcgr2 |
| Alternative Name(s) | FCGR3, IGFR3; FCGR2, IGFR2; FC Receptor |
| Format | In Vivo Ready™ |
| Preparation | This monoclonal antibody preparation was purified from tissue culture supernatant via affinity chromatography. For In Vivo Ready™ (IVR) products, each preparation is also evaluated for endotoxin levels using the LAL assay. It is recommended to store the product undiluted at 4°C. Do not freeze. |
| Application Notes | This purified format is guaranteed to be >90% pure as determined by SDS-PAGE analysis. Citations are provided as a convenience to you - please consult Materials and Methods sections for additional details about the use of any product in these publications. |
| Endotoxin Level | Less than or equal to 0.01 EU/ug, as determined by the LaL assay |
| Storage Conditions | 2-8°C |
Stephen TL, Wilson BS, and Laufer TM. 2012. Proc. Natl. Acad. Sci. 109: 7415-7420. (Blocking- Immunofluorescence microscopy)
Yamaji O, Nagaishi T, Totsuka T, Onizawa M, Suzuki M, Tsuge et al. 2012. J. Immunol. 188:2524-2536. (Blocking - in vitro)
Shimazu T, Iida R, Zhang Q, Welner RS, Medina KL, Alberola-Ila J, and Kincade PW. 2012. Blood. 119:4889-4897. (Blocking – Flow cytometry)
Stoeker L, Nordone S, Gunderson S, Zhang L, Kajikawa A, LaVoy A, Miller M, Klaenhammer TR, and Dean GA. 2011. Clin. Vaccine Immunol. 18: 1834-1844. (Blocking – Flow cytometry)
Beretta F, St.-Pierre J, Piccirillo CA, and Stevenson MM. 2011. J. Immunol. 186: 4862-4871. (Blocking - Flow cytometry)
Coudert JD, Scarpellino L, Gros F, Vivier E, and Held W. 2008 Blood. 111: 3571-3578. (Immunoprecipitation)
Provided below are standard protocols that you may find useful for product applications.
Background
The 2.4G2 antibody is specific for a common epitope found in the extracellular regions of mouse Fc-receptors Fc-gamma II (CD32) and Fc-gamma III (CD16). As these are receptors for the Fc portion of mouse IgG, they may also bind laboratory antibody preparations and products used in a variety of cell analysis protocols such as flow cytometry, immunohistochemistry and functional cell assays. The 2.4G2 antibody is therefore widely used as a pre-treatment reagent to block binding of specific antibodies of interest, e.g. fluorescently conjugated antibodies, to Fc receptors via their Fc domains and contributing to “non-specific” staining.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
